Published on February 15, 2020
Background
Scientists report promising activity of the novel an oral first-in-class MK-6482 drug that targets a key driver of clear cell Renal Cell Carcinoma (ccRCC) in patients with metastatic disease.
In the vast majority of patients with clear cell Renal Cell Carcinoma (RCC), a tumor suppressor protein known as Von Hippel-Lindau (VHL) is not functional. As a result, hypoxia inducible factor (HIF) proteins accumulate inside the tumor cell, wrongly signaling there is a shortage of oxygen and activating the formation of blood vessels, fueling tumor growth.
Understanding this abnormal process has paved the way for new cancer drugs – MK-6482 being one of them and is distinct in that it targets HIF-2a directly leading to blocking cancer cell growth, proliferation and abnormal blood vessel formation.
Results
The study included 55 patients with advanced clear cell kidney cancer who had an average of 3 prior lines of therapies.
- Researchers from Dana-Farber Cancer Institute report that 24% of patients had their tumor shrunk given MK-6482 and it was seen in all risk categories – poor, intermediate and good and in a heavily refractory.
- 56% of patients had their disease stopped from growing and progressing.
- That brings us to 80% of patients who responded to MK-6482.
- The median time until progression under the treatment was 11 months.
Adverse Events
MK-6482 was well-tolerated with a favorable safety profile.
The most common adverse events were anemia, fatigue, dyspnea, nausea and cough. No serious drug-related adverse events were observed.
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 for free service matching:
Call center +44.2082.426.039